Mutation de résistance ROS1 G2032R
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | BIO-ROS1-G2032R |
|---|---|
| Type | Biomarqueur |
| Alias | ROS1 G2032R — мутація резистентностіROS1 p.G2032RMutation ROS1 devant solvant |
| État | reviewed 2026-04-27 | pending_clinical_signoff |
| Maladies | Aucune déclaration |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 SRC-TRIDENT1-DRILON-2024 |
Données biomarqueurs
| Type de biomarqueur | gene_mutation |
|---|---|
| Détails de la mutation | {"exon": "38", "functional_impact": "resistance to crizotinib, ceritinib, entrectinib, lorlatinib; sensitive to repotrectinib (TRIDENT-1)", "gene": "ROS1", "hgvs_protein": "p.G2032R", "variant_type": "missense"} |
| Mesure | MéthodectDNA NGS preferred at TKI progression; tumor re-biopsy NGS acceptable Unitéscategorical (positive | negative); VAF % when reported Exigence de sensibilitéL'émergence sous-clonal est fréquente — VAF ≥0,5 % (ADN cf) actionnable |
| Recherche de la faisabilité | {"générique": "ROS1", "variante":"G2032R"} |
| Biomarqueurs connexes | BIO-ROS1-FUSION |
Notes
Most common acquired resistance mutation in ROS1-rearranged NSCLC treated with crizotinib (~40% of resistance cases). Solvent-front position structurally analogous to ALK G1202R; confers cross- resistance to crizotinib, ceritinib, entrectinib, and lorlatinib. Repotrectinib (TPX-0005), a next-generation macrocyclic ROS1/TRK inhibitor, demonstrates activity in G2032R-positive patients per TRIDENT-1 (Drilon 2024, NEJM): ORR ~38-58% in TKI-pretreated cohort including G2032R-positive subset. FDA-approved 2023 for ROS1+ NSCLC (TKI-naive and post-TKI). Standard recommendation when G2032R detected on prior ROS1-TKI failure.
Utilisé par
No reverse references found in the YAML corpus.